Retatrutide Weight Loss Results: What the Clinical Trial Data Shows

The Headline Results: 28.3% at 80 Weeks

The current headline number is 28.3% mean weight loss at 80 weeks on the 12 mg weekly dose, from the Phase 3 TRIUMPH-1 trial (n=2,339), announced May 21, 2026. The older 24.2% figure came from the 48-week Phase 2b trial and is still quoted widely; it has been superseded. To put the Phase 3 number in context:

• 200 lb person: 48 lbs weight loss
• 250 lb person: 60 lbs weight loss
• 300 lb person: 72 lbs weight loss

This represents the highest weight loss achieved by any approved or investigational GLP-1 medication. It is 61% greater than semaglutide's 15% and 8% greater than tirzepatide's 22.5%.

The clinical significance of this improvement cannot be overstated. For people who struggled to lose 30 lbs on semaglutide, retatrutide offers the potential to lose 48 lbs or more — a life-changing difference.

Phase 3 TRIUMPH-1: The Current Data

TRIUMPH-1 (NCT05929066) randomized 2,339 adults with obesity or overweight plus at least one weight-related comorbidity, excluding people with diabetes, to 4 mg, 9 mg, 12 mg, or placebo. Treatment ran 80 weeks. Topline results were announced by Eli Lilly on May 21, 2026. Mean baseline weight in the 12 mg arm was 248.5 lb at a BMI of 40.0.

• 4 mg: 47.2 lb mean loss, 19.0% of body weight
• 9 mg: 64.4 lb mean loss, 25.9%
• 12 mg: 70.3 lb mean loss, 28.3%
• 30% or greater loss: achieved by 45.3% of the 12 mg group
• Dropped below BMI 30: 65.3% of the 12 mg group, including 37.5% of those who entered with class 3 obesity
• Waist circumference: down 24.1 cm (9.5 inches) on 12 mg

A prespecified blinded extension continued 532 participants with baseline BMI of 35 or higher to 104 weeks at maximum tolerated dose. Those originally randomized to 12 mg reached 85.0 lb mean loss, 30.3% of a 268.3 lb baseline. Read that number carefully: it comes from a selected subgroup that tolerated two years of treatment, not from everyone who started the trial.

Tolerability worsened with dose. Discontinuation for adverse events was 4.1% at 4 mg, 6.9% at 9 mg, and 11.3% at 12 mg, against 4.9% on placebo. The lowest dose was better tolerated than placebo; the top dose more than doubled the placebo rate. Nausea ran 28.6%, 38.4%, and 42.4% across the three arms versus 14.8% on placebo. Full breakdown at retatrutide TRIUMPH-1 results and retatrutide side effects.

Detailed data was slated for presentation at the American Diabetes Association Scientific Sessions. Peer-reviewed publication had not appeared as of this writing, so these figures come from a company announcement and may be revised. TRIUMPH-2 (type 2 diabetes) and TRIUMPH-3 (established cardiovascular disease) had not read out.

Phase 2b Trial Results in Detail

The Phase 2b trial that demonstrated 24.2% weight loss at 48 weeks is worth examining in detail, though the Phase 3 TRIUMPH-1 trial has since superseded it as the strongest evidence for retatrutide's efficacy.

Trial design:

• Study name: Phase 2b dose-finding trial for retatrutide
• Study population: Non-diabetic adults with obesity (BMI 30-60)
• Randomization: Multiple dose groups (3, 6, 9, 12 mg weekly) plus placebo
• Study duration: 48 weeks of treatment
• Primary endpoint: Weight loss at week 48
• Participants: ~750 participants across all arms

Results by dose:

• 3 mg weekly: 10-12% weight loss at 48 weeks
• 6 mg weekly: 16-18% weight loss at 48 weeks
• 9 mg weekly: 22-23% weight loss at 48 weeks
• 12 mg weekly: 24.2% weight loss at 48 weeks
• Placebo: 2-3% weight loss at 48 weeks (normal diet variation)

The dose-response relationship is clear: higher doses produce greater weight loss up to 12 mg. Whether even higher doses would produce more weight loss is unknown, as 12 mg was selected as the maintenance dose.

Timing of weight loss: Weight loss was not linear across the 48 weeks:

• Weeks 1-4: Initial rapid weight loss as appetite suppression takes effect (3-5 lbs)
• Weeks 4-12: Continued rapid weight loss as dose escalation completes (15-20 lbs total)
• Weeks 12-24: Moderate weight loss rate (25-30 lbs total)
• Weeks 24-48: Slower weight loss rate with gradual plateau (40-48 lbs total)

This pattern suggests weight loss plateaus around 48 weeks, though longer-term data would confirm whether this is a true plateau or just slower continued weight loss.

Phase 1b Data: Earlier Results

Earlier Phase 1b trials, which tested lower doses and shorter durations, also provide weight loss evidence:

Phase 1b trial results:

• Up to 17.5% weight loss at 36 weeks (lower maintenance dose than Phase 2b)
• Linear dose-response up to doses tested
• Rapid weight loss in the first 12 weeks, then slower plateau
• Good tolerability at lower doses

The Phase 1b data was important because it demonstrated dose-related weight loss and safety at lower doses, which informed the dose selection for Phase 2b. The Phase 2b data then showed that even higher doses (12 mg) could be tolerated and produced even better weight loss (24.2%).

Body Composition: What Gets Lost?

Total weight loss is important, but what matters more is what type of weight is lost. Ideally, you want to lose fat and retain muscle.

Retatrutide body composition data:

In Phase 2b trials, approximately 70-80% of weight loss was fat mass, and 20-30% was lean muscle tissue. This breakdown is similar to semaglutide and tirzepatide.

For a 200 lb person losing 48 lbs on retatrutide:

• Fat loss: 34-38 lbs (most desirable)
• Muscle loss: 10-14 lbs (less desirable)

Can you prevent muscle loss? Yes, research shows that resistance training and adequate protein intake can reduce muscle loss to 15-20% of total weight loss. Recommendations:

• Resistance training 2-4 times per week during weight loss
• Protein intake of 1.6-2.2 grams per kilogram of body weight daily
• Maintaining or slightly increasing strength during weight loss

With these interventions, muscle loss could be reduced from 14 lbs to 8 lbs, meaning 40 lbs of the 48 lbs lost would be fat. This is important especially for older adults, who need to preserve muscle for strength and function.

Metabolic Improvements Beyond Weight Loss

Weight loss numbers are impressive, but retatrutide also improves several metabolic markers:

Glucose control: In non-diabetic participants, fasting glucose decreased approximately 5-10% from baseline. HbA1c (a 3-month average of blood glucose) decreased ~0.5-1%, even in people without diabetes. This indicates improved insulin sensitivity.

Insulin sensitivity: HOMA-IR (a measure of insulin resistance) improved dramatically in Phase 2b trials, suggesting retatrutide directly improves how well your cells respond to insulin, independent of weight loss.

Lipid profile: Total cholesterol decreased ~10-15%, LDL cholesterol decreased ~15-20%, and triglycerides decreased ~20-30%. HDL cholesterol increased slightly (which is favorable). These changes are due to both weight loss and direct effects of GIP and glucagon activation on hepatic lipid metabolism.

Liver health: Intrahepatic lipid content (fat in the liver) decreased significantly — approximately 30-40% reduction in people with fatty liver disease. This is clinically important because liver fat is associated with metabolic disease and liver fibrosis.

Blood pressure: Systolic blood pressure decreased approximately 5-10 mmHg and diastolic ~3-5 mmHg, similar to what would be expected from weight loss alone.

Inflammation markers: C-reactive protein (CRP), a marker of systemic inflammation, decreased ~30%, suggesting retatrutide has anti-inflammatory effects beyond weight loss.

These metabolic improvements demonstrate that retatrutide's benefits extend beyond pure weight loss — it produces genuine metabolic health improvement.

Retatrutide Weight Loss vs Every Other GLP-1 Drug

Retatrutide has produced the largest mean weight loss reported in a Phase 3 obesity trial to date. One caution about the table: these are separate trials with different durations, populations, and baseline weights, so the rows are not directly comparable. No trial has ever randomized patients between retatrutide and tirzepatide. The comparison is indirect, and indirect comparisons tend to exaggerate gaps.

Individual Variation in Weight Loss

While the 28.3% Phase 3 average (12 mg at 80 weeks) is impressive, individual results vary considerably. Some people lose 30%+ of body weight, while others lose 15-20%.

Factors that affect weight loss on retatrutide:

• Starting weight: People with higher starting weights tend to lose more absolute pounds but similar percentages.
• Insulin resistance: People with greater insulin resistance (measured by HOMA-IR or fasting insulin) may respond better, especially to the GIP and glucagon components.
• Diet quality: Better dietary adherence leads to greater weight loss. Retatrutide suppresses appetite but doesn't prevent poor food choices.
• Physical activity: Exercise, especially resistance training, enhances weight loss and preserves muscle.
• Age: Older adults may lose weight slightly slower than younger adults.
• Genetic factors: Inherited metabolic factors affect response to GLP-1 drugs. Some people are "responders" (20%+ loss) and others are "non-responders" (5-10% loss).
• Sleep and stress: Poor sleep and chronic stress reduce weight loss efficacy.
• Medication adherence: Perfect adherence (injecting every 7 days) produces better results than inconsistent use.

A 200 lb person might lose anywhere from 20 lbs (10%) to 60+ lbs (30%) depending on these factors. On average, the Phase 3 12 mg figure of 28.3% at 80 weeks is the current expectation, but individual outcomes vary.

Who Are the Best Candidates for Retatrutide Weight Loss?

Not everyone needs or should take retatrutide. Here are the best candidates:

Ideal candidates:

• BMI 30+ without major health conditions, OR BMI 27+ with weight-related comorbidities (diabetes, hypertension, heart disease)
• Failed weight loss on semaglutide (lost less than 10% or plateaued)
• Failed previous weight loss attempts with diet and exercise alone
• No personal or family history of thyroid cancer or multiple endocrine neoplasia (MEN2)
• No history of pancreatitis
• Motivated to lose weight and willing to make lifestyle changes

Good candidates:

• Starting GLP-1 therapy for the first time and want maximum efficacy
• Have metabolic syndrome (insulin resistance + hypertension + dyslipidemia + obesity)
• Have type 2 diabetes that hasn't responded well to medications
• Have fatty liver disease that would benefit from rapid weight loss and metabolic improvement

Less ideal candidates:

• Already achieving good results on semaglutide or tirzepatide
• Limited access to specialist care or follow-up
• Cannot afford the medication or insurance won't cover it
• Contraindications to GLP-1 drugs (personal/family history of MTC, active cancer)

Long-Term Weight Maintenance on Retatrutide

An important but unresolved question is whether people maintain weight loss after achieving maximum weight loss. Limited long-term data is available from clinical trials.

Semaglutide and tirzepatide data on weight maintenance: In trials extending beyond the weight loss phase, patients generally maintained weight loss as long as they continued the medication. When stopped, approximately 50% of weight loss was regained within 1 year.

Expected retatrutide maintenance: Retatrutide will likely show similar maintenance patterns — weight maintained on the drug, significant regain after discontinuation. This suggests retatrutide is a long-term maintenance therapy rather than a short-term weight loss tool.

Maintenance dosing: It's unclear whether patients can maintain weight loss on lower doses than those used for weight loss. Tirzepatide trials suggest similar doses are needed for maintenance as for initial weight loss. Retatrutide may be similar, though lower maintenance doses might be possible given the triple mechanism.

Retatrutide vs Weight Loss Surgery

Retatrutide's 28.3% at 80 weeks lands inside the range reported for gastric sleeve surgery (~25-30%) and approaches gastric bypass (~30-35%). In the 104-week extension the 12 mg arm reached 30.3%, and 45.3% of the 12 mg group in the main trial lost 30% or more of body weight. How do they compare?

For many patients, retatrutide will be preferable to surgery: it's noninvasive, reversible, has minimal risk, and produces comparable weight loss to sleeve surgery. However, for those seeking maximum weight loss, surgery may still be preferable.

Related Guides

• Retatrutide vs Tirzepatide: Phase 3 Data Compared
• Retatrutide TRIUMPH-1: Full Phase 3 Results
• Retatrutide vs Semaglutide: How Much More Weight Loss?
• Retatrutide Mechanism of Action: Why It Works Better
• Which GLP-1 Is Best for Weight Loss? Complete Comparison